Skip to main content

PRESS RELEASES

Date Title  
Toggle Summary Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates
- Company preparing to initiate SER-287 Phase 2b study for ulcerative colitis - - Initiation of SER-401 clinical study expected in patients with metastatic melanoma treated with checkpoint inhibitors by year end - - Recent Seres R&D event highlighted microbiome scientific leadership across several
Toggle Summary Seres Therapeutics to Host Second Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on August 2, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 25, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on August 2, 2018 at 8:30 a.m. ET to discuss second quarter 2018 financial results and provide a general business update.
Toggle Summary Seres Therapeutics to Present at Two Upcoming June Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 1, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences: Jefferies 2018 Global Healthcare Conference : a corporate overview will be presented on Wednesday, June 6 at 4:30 p.m.
Toggle Summary Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 17, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that the Company will host a Microbiome R&D Day on Thursday, May 24, 2018 , from 8:00 a.m.–10:30 a.m. ET in New York, NY . The event will feature presentations from Seres management and
Toggle Summary Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates
Toggle Summary Seres Therapeutics to Host First Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on May 9, 2018 at 8:30 a.m. ET to discuss first quarter 2018 financial results and provide a general business update.
Toggle Summary Seres Therapeutics to Present at Two Upcoming May Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 4, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced it will attend each of the following upcoming healthcare conferences: Deutsche Bank 43 rd Annual Health Care Conference : The company will participate in 1x1 meetings on Wednesday, May 9 in
Toggle Summary Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 17, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that new preclinical data supporting the development of microbiome therapeutics for immuno-oncology (leveraging gut microbiota to impact tumor immunotherapy) 1 will be presented today by
Toggle Summary Seres Therapeutics to Present at Two Upcoming March Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 9, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences: The 38 th Annual Cowen & Co. Health Care Conference : a corporate overview will be presented on Wednesday, March 14 at
Toggle Summary Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
- Positive SER-287 Phase 1b clinical and microbiome results support further development; Company plans to initiate next clinical trial in mid-2018 - - Preliminary Phase 1b study data obtained for SER-262, the first ever rationally-designed fermented microbiome therapeutic candidate evaluated in

Back to top